The clinical value of EEG monitoring and silver nanoparticles to detect the levels of serum Nesfatin-1, S100β and neuron-specific enolase in evaluating the severity and prognosis of epilepsy

Abstract

This study aimed to explore the clinical value of electroencephalogram (EEG) monitoring and the use of silver nanoparticles to detect serum levels of Nesfatin-1, S100β and Neuron-specific enolase (NSE) in assessing the severity and prognosis of epilepsy. A total of 54 epilepsy patients treated at our hospital from June 2017 to June 2019 were selected as the epilepsy group, and 54 healthy subjects were selected as the control group. EEG and serum levels of Nesfatin-1, S100β, and NSE in epilepsy patients without seizure and within 1 hour of seizure were ascertained and compared. The Liverpool Seizure Severity Scale (LSSS) score was used to evaluate the severity of epilepsy in patients, and the correlation between EEG findings and serum Nesfatin-1, S100β , and NSE levels was analyzed. ROC analysis was also conducted on the levels of the three factors. The patients were followed up for 1 year, the mortality rate was calculated, and the levels of Nesfatin-1, S100β, and NSE in deceased and non-deceased patients were compared. There were 50 cases (92.6%) with EEG abnormalities in the epilepsy group and 31 cases (57.4%) with epileptic EEGs in the epileptic non-seizure group. There was a significant difference in the proportion of abnormal EEGs between the two groups of epilepsy patients (P <0.05); the biomarker (Nesfatin-1, S100β, and NSE) serum levels were higher in both the non-seizure group and epileptic group than the control group, and the levels in the seizure group were higher than those in the non-seizure group (P < 0.05); seizures in patients with epilepsy were positively correlated with EEG abnormalities and biomarker serum levels. There was, however, no significant correlation between EEG abnormalities and biomarker serum levels. ROC analysis of epilepsy patients and their serum levels of Nesfatin-1, S100β and NSE showed that the area under the curve corresponding to each index was 0.850, 0.881, and 0.868, respectively (P < 0.05). With regards to deceased patients, the proportion with an abnormal EEG was 100% (15/15), which was higher than 41.0% (16/39) of non-deceased patients. Serum levels of biomarkers were also significantly higher than those in non-deceased patients (P < 0.05). Changes in EEG and biomarker serum levels were closely related to the severity of epilepsy. The proportion of patients with abnormal EEGs during seizure periods was higher, and the expression of serum Nesfatin-1, S100β and NSE was also increased, which means they can be used as markers of epilepsy and have an impact on its prognosis